Table 1.
Characteristics of patients who initiated sofosbuvir regimens for hepatitis C virus (HCV) infection between January 2014 and June 2016 by known or unknown 12-week sustained virologic response (SVR) status
| Characteristic | Known SVR n (%) |
Unknown SVR n (%) |
|---|---|---|
| Overall | 355 | 80 |
| Age category | ||
| < 50 years | 71 (20) | 34 (42) |
| ≥ 50 years | 284 (80) | 46 (58) |
| Gender | ||
| Male | 183 (52) | 39 (49) |
| Female | 172 (48) | 41 (51) |
| Race/ethnicity | ||
| Non-Hispanic White | 201 (57) | 50 (63) |
| Non-Hispanic Black | 107 (30) | 15 (19) |
| Hispanic | 30 (8.5) | 10 (13) |
| Othera | 17 (4.8) | 5 (6.3) |
| Insurance type | ||
| Uninsured | 274 (77) | 72 (90) |
| Medicare or medicaid | 51 (14) | 5 (6.3) |
| Private | 30 (8.5) | 3 (3.8) |
| Current alcohol use b | ||
| Yes | 103 (30) | 23 (30) |
| No | 240 (70) | 54 (70) |
| History of illicit drug use b | ||
| Yes | 53 (16) | 10 (13) |
| No | 286 (84) | 67 (87) |
| Body mass index | ||
| Obese (≥ 30) | 153 (43) | 26 (33) |
| Overweight (25–29.9) | 113 (32) | 30 (38) |
| Normal (18.5–24.9) | 81 (23) | 24 (30) |
| Underweight (< 18.5) | 8 (2.3) | 0 (0) |
| HCV genotype | ||
| 1 | 275 (77) | 62 (78) |
| 2 | 43 (12) | 7 (8.8) |
| 3 | 33 (9.3) | 9 (11) |
| 4 or 6 | 4 (1.1) | 2 (2.5) |
| HIV | ||
| Yes | 17 (4.8) | 0 (0) |
| No | 338 (95) | 80 (96) |
| Cirrhosis | ||
| Yes | 87 (25) | 13 (16) |
| No | 268 (75) | 67 (84) |
| Decompensated cirrhosis b | ||
| Yes | 16 (19) | 2 (14) |
| No | 70 (81) | 12 (86) |
| Prior HCV treatment c | ||
| Yes | 52 (15) | 9 (11) |
| No | 302 (85) | 71 (89) |
| Treatment regimen | ||
| Ledipasvir/sofosbuvir | 239 (67) | 62 (78) |
| Ribavirin/sofosbuvir | 116 (33) | 18 (22) |
aIncludes Asian and mixed ethnicity
bAmong individuals with cirrhosis
cMissing values for some patients